Support teaching, research, and patient care.
Golara Honari, MD, a specialist in eczematous dermatoses including contact dermatitis atopic dermatitis, and occupational dermatoses. A native of Iran, Dr. Honari earned her medical degree from Iran’s University of Medical Sciences in 1999 and completed her residencies in Internal Medicine and Dermatology at the Cleveland Clinic. While at the Cleveland Clinic, she also completed a Fellowship in Contact Dermatitis and Environmental Dermatology. Her professional interests include eczematous dermatoses, contact dermatitis, systemic hypersensitive, phototoxicity and photo allergies, and occupational dermatology. Dr. Honari is currently a member of the Board of Directors at the American Contact Dermatitis Society and serves as a mentor at the International Society of Dermatology in the arena of Contact Dermatitis. Her research is in the fields of contact dermatitis, atopic dermatitis, and cutaneous and systemic hypersensitivity reactions.
I'm interested in a better understanding of the clinical and molecular mechanisms of eczematous dermatoses and the effects of environmental and occupational exposures on the skin. Also interested in understanding the burden of eczematous disorders on individual patients and the health care system and means to improve clinical care and access.
COVID-19 Messaging for Vaccination
This study will distribute videos of health professionals encouraging Covid-19 vaccination to
a large sample of Facebook users, and will test the most effective ways to maximize diffusion
of this vaccine-related content to increase vaccination rates. The study sample will be U.S.
states where vaccination rates remained low in fall 2021. The experimental design is an RCT
with 4 groups, randomized at the county level: 1) a control group which receives no
intervention, 2) a treatment group in which Facebook users receive ads which include videos
of health professionals telling them to get vaccinated, 3) a treatment group in which
Facebook users receive ads which include videos of health professionals encouraging them to
help their friends to get vaccinated, and 4) a treatment group in which Facebook users
receive ads which include videos of health professionals encouraging them to get their most
influential friends to help their friends get vaccinated. In treatments 3 and 4, participants
will have the option to sign up to be a "vaccine ambassador," in which case they will get
notifications when the study team posts new vaccine-related content, and will receive
reminders about encouraging their friends to be vaccinated. The vaccine ambassadors will also
be entered into a lottery to win prizes. The study team is building a website to host the
videos of health professionals which answer common questions about Covid-19 vaccination. The
investigators will measure engagement with the vaccine-related content as well as assess
effects on vaccination rates at the county level.
View full details
A Safety Study of SEA-BCMA in Patients With Multiple Myeloma
This trial will study SEA-BCMA to find out whether it is an effective treatment for multiple
myeloma (MM) and what side effects (unwanted effects) may occur.
The study will have several parts. In Parts A and B, participants get SEA-BCMA by itself.
This part of the study will find out how much SEA-BCMA should be given for treatment and how
often. It will also find out how safe the treatment is and how well it works.
In Part C of the study, participants will get SEA-BCMA and dexamethasone. In Part D,
participants will get SEA-BCMA, dexamethasone, and pomalidomide. Dexamethasone and
pomalidomide are both drugs that can be used to treat multiple myeloma. These parts of the
study will find out whether these drugs are safe when used together.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.